When is major depressive disorder considered to be in partial remission, and what PHQ‑9 score defines that range?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Major Depressive Disorder in Partial Remission: PHQ-9 Score Range

Partial remission in major depressive disorder is not formally defined by specific PHQ-9 score cutoffs in clinical guidelines, but based on the available evidence, a PHQ-9 score of approximately 5-9 represents the practical range for partial remission in clinical practice.

Understanding Partial Remission

The concept of partial remission refers to a state where depressive symptoms have improved but have not completely resolved. While the DSM-5 defines remission based on symptom criteria rather than specific scale scores, measurement-based care requires practical cutoffs 1.

PHQ-9 Score Interpretation for Remission Status

Full Remission:

  • PHQ-9 score <5 is the established threshold for full remission 2, 3, 4
  • This represents minimal to no clinically significant depressive symptoms
  • Corresponds to symptom-free status

Partial Remission (Practical Range):

  • PHQ-9 scores 5-9 represent the zone where patients have residual symptoms but significant improvement
  • This range falls between full remission (<5) and mild depression (≥10)
  • Patients show meaningful response (≥50% reduction from baseline) but haven't achieved complete symptom resolution 2

Active Depression:

  • PHQ-9 scores ≥10 indicate ongoing clinically significant depression requiring continued active treatment 5, 6

Clinical Context and Nuances

Why This Range Matters

Research demonstrates that residual symptoms (partial remission) carry significant clinical implications 7:

  • Relapse rates are 3-6 times higher in patients with residual symptoms versus full remission
  • Associated with increased disability, more healthcare visits, and higher suicide risk
  • Approximately one-third of treated patients achieve only partial remission rather than full remission

Response vs. Remission Distinction

The evidence distinguishes between:

  • Response: ≥50% reduction in PHQ-9 score from baseline (but may still have scores ≥5) 2
  • Partial Remission: Improvement with residual symptoms (PHQ-9 5-9 range)
  • Full Remission: PHQ-9 <5 2, 3, 4

Important Caveats

No Official DSM-5 PHQ-9 Cutoff: The DSM-5 defines partial remission based on symptom count and duration (some symptoms present but full criteria not met for at least 2 weeks), not specific scale scores 1. However, measurement-based care requires practical thresholds.

Minimal Clinically Important Difference: A change of 5 points on the PHQ-9 represents the minimal clinically important difference for individual patients 2. This supports the 5-point threshold as meaningful.

Alternative Scales Show Similar Patterns: When comparing the PHQ-9 to other depression measures, the remission threshold of <5 shows good agreement with clinician-rated scales like the Hamilton Depression Rating Scale (HAM-D ≤7) 8, 3.

Clinical Algorithm for Assessment

When evaluating remission status:

  1. PHQ-9 <5: Consider full remission; monitor for relapse but may consider treatment tapering with appropriate follow-up

  2. PHQ-9 5-9: Partial remission zone

    • Reassess treatment adequacy
    • Consider treatment optimization or augmentation
    • Increase monitoring frequency given elevated relapse risk
    • Address residual symptoms aggressively to prevent relapse
  3. PHQ-9 ≥10: Active depression requiring continued or intensified treatment 6, 9

Critical Point: Patients in partial remission (PHQ-9 5-9) should not be considered "adequately treated" given the substantially elevated relapse risk. The treatment goal should remain full remission (PHQ-9 <5) to optimize long-term outcomes and reduce relapse rates 7.

Related Questions

What does a PHQ‑9 score of 17 indicate and how should major depressive disorder be diagnosed based on this score?
Should I document the patient's diagnosis as major depressive disorder in remission given a prior depressive episode, a PHQ‑9 score of 0, and ongoing maintenance therapy?
Should an 11-year-old be screened with the CRAFFT questionnaire and the PHQ‑9 (Patient Health Questionnaire‑9) for depression and substance use?
What is the recommended course of action for a patient with depressive symptoms based on their Patient Health Questionnaire-9 (PHQ-9) rating scale results?
What is the recommended treatment for a 19-year-old female patient with moderate to severe depression, as indicated by a Patient Health Questionnaire-9 (PHQ-9) score of 16, Generalized Anxiety Disorder (GAD) mood swings, and recent agitation, who does not smoke or consume alcohol?
What is the likely diagnosis and recommended management for a 65-year-old woman with unilateral joint pain that is worse at night and in the morning with stiffness that improves with movement?
Can Lexapro (escitalopram) cause nosebleeds?
In a pediatric patient with crackles on lung auscultation, what is the appropriate evaluation and management for possible lower respiratory tract infection or pneumonia?
What does it mean that my EBV antibody tests show positive EBV early antigen IgG, EBV nuclear antigen IgG, and EBV viral capsid antigen IgG?
Why is low‑molecular‑weight heparin (LMWH) preferred over unfractionated heparin (UFH) in patients with septic shock?
What is the recommended schedule, dosing, and timing for hepatitis B vaccination (and hepatitis B immune globulin if indicated) in premature neonates, considering clinical stability and maternal HBsAg status?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.